Table 1.
Patient demographics and baseline characteristics
| Characteristic | PBO, n = 221 | UPA 15 mg, n = 221 | UPA 30 mg, n = 219 |
|---|---|---|---|
| Age (years), mean ± SD | 56.0 ± 12.2 | 55.3 ± 11.5 | 55.8 ± 11.3 |
| Female, n (%) | 166 (75.1) | 182 (82.4) | 172 (78.5) |
| White, n (%) | 187 (84.6) | 188 (85.1) | 186 (84.9) |
| Duration RA diagnosis (years), mean ± SD | 7.2 ± 7.5 | 7.3 ± 7.9 | 7.3 ± 7.9 |
| Duration of RA (≥ 5 years), n (%) | 99 (44.8) | 98 (44.3) | 102 (46.6) |
| CDAI, mean ± SD | 37.8 ± 11.8 | 38.3 ± 11.9 | 38.6 ± 12.7 |
| DAS28-CRP, mean ± SD | 5.6 ± 0.8 | 5.7 ± 1.0 | 5.7 ± 0.9 |
| Seropositive for RF, n (%) | 164 (74.2) | 163 (73.8) | 146 (66.7) |
| Anti-CCP antibody positive, n (%) | 167 (75.9) | 174 (79.1) | 155 (70.8) |
| Tender joint count (of 68), mean ± SD | 24.7 ± 15.0 | 25.2 ± 13.8 | 26.2 ± 14.3 |
| Swollen joint count (of 66), mean ± SD | 15.4 ± 9.2 | 16.0 ± 10.0 | 16.2 ± 10.6 |
| csDMARD use at baseline, n (%) | |||
| MTX alone | 141 (64.1) | 122 (55.5) | 136 (62.1) |
| MTX plus other csDMARD | 49 (22.3) | 47 (21.4) | 39 (17.9) |
| csDMARD other than MTX | 30 (13.6) | 51 (23.2) | 44 (20.1) |
| Missing | 1 (< 1) | 1 (< 1) | 0 |
CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-CRP Disease Activity Score 28 using C-reactive protein, MTX methotrexate, PBO placebo, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, UPA upadacitinib